178 related articles for article (PubMed ID: 34561502)
1. Dissection of the bone marrow microenvironment in hairy cell leukaemia identifies prognostic tumour and immune related biomarkers.
Koldej RM; Prabahran A; Tan CW; Ng AP; Davis MJ; Ritchie DS
Sci Rep; 2021 Sep; 11(1):19056. PubMed ID: 34561502
[TBL] [Abstract][Full Text] [Related]
2. Flow cytometry of peripheral blood and bone marrow cells from patients with hairy cell leukemia: phenotype of hairy cells, lymphocyte subsets and detection of minimal residual disease after treatment.
Babuŝíková O; Tomová A; Kusenda J; Gyárfás J
Neoplasma; 2001; 48(5):350-7. PubMed ID: 11845978
[TBL] [Abstract][Full Text] [Related]
3. Combination treatment of 2-chlorodeoxyadenosine and type I interferon on hairy cell leukemia-like cells: cytotoxic effect and MHC-unrestricted killer cell regulation.
Reiter Z; Tomson S; Ozes ON; Taylor MW
Blood; 1993 Apr; 81(7):1699-708. PubMed ID: 8096405
[TBL] [Abstract][Full Text] [Related]
4. Flow cytometry of blood and bone marrow cells from patients with hairy cell leukemia: phenotype of hairy cells and lymphocyte subsets after treatment with 2-chlorodeoxyadenosine.
Juliusson G; Lenkei R; Liliemark J
Blood; 1994 Jun; 83(12):3672-81. PubMed ID: 7911341
[TBL] [Abstract][Full Text] [Related]
5. Successful treatment of patients with hairy cell leukemia (HCL) using a single cycle of 2-chloro-2'-deoxyadenosine (CdA).
Jehn U; Gawaz M; Grunewald R; Hill W; Lorenz B; Stôtzer O
Anticancer Res; 1993; 13(5C):1809-14. PubMed ID: 7903521
[TBL] [Abstract][Full Text] [Related]
6. Basic fibroblast growth factor is expressed by CD19/CD11c-positive cells in hairy cell leukemia.
Gruber G; Schwarzmeier JD; Shehata M; Hilgarth M; Berger R
Blood; 1999 Aug; 94(3):1077-85. PubMed ID: 10419901
[TBL] [Abstract][Full Text] [Related]
7. 2-chlorodeoxyadenosine (cladribine) in the treatment of hairy cell leukemia and hairy cell leukemia variant: 7-year experience in Poland.
Robak T; Błasińska-Morawiec M; Błoński J; Hellmann A; Hałaburda K; Konopka L; Kotlarek-Haus S; Potoczek S; Hansz J; Dmoszyńska A; Urasiński I; Zdziarska B; Dwilewicz-Trojaczek J; Hołowiecki J; Skotnicki AB
Eur J Haematol; 1999 Jan; 62(1):49-56. PubMed ID: 9918312
[TBL] [Abstract][Full Text] [Related]
8. A comprehensive immunophenotypic marker analysis of hairy cell leukemia in paraffin-embedded bone marrow trephine biopsies--a tissue microarray study.
Tóth-Lipták J; Piukovics K; Borbényi Z; Demeter J; Bagdi E; Krenács L
Pathol Oncol Res; 2015 Jan; 21(1):203-11. PubMed ID: 24903677
[TBL] [Abstract][Full Text] [Related]
9. Detection of minimal residual disease by immunostaining of bone marrow biopsies after 2-chlorodeoxyadenosine for hairy cell leukemia.
Hakimian D; Tallman MS; Kiley C; Peterson L
Blood; 1993 Sep; 82(6):1798-802. PubMed ID: 7691237
[TBL] [Abstract][Full Text] [Related]
10. [Hairy cell leukemia--a potentially curable malignancy. Selected aspects of purine analog therapy].
Rucińska M; Machaczka M; Załuska A; Skotnicki AB
Przegl Lek; 1998; 55(7-8):400-6. PubMed ID: 10021885
[TBL] [Abstract][Full Text] [Related]
11. Minimal residual disease in hairy-cell leukemia after treatment with 2-chlorodeoxyadenosine.
Konwalinka G; Schirmer M; Hilbe W; Fend F; Geisen F; Knoblechner A; Petzer A; Thaler J
Blood Cells Mol Dis; 1995; 21(2):142-51. PubMed ID: 8846043
[TBL] [Abstract][Full Text] [Related]
12. Treatment of hairy cell leukaemia (HCL) with 2-chlorodeoxyadenosine (2-CdA): identification of parameters predictive of adverse effects.
Legrand O; Vekhoff A; Marie JP; Zittoun R; Delmer A
Br J Haematol; 1997 Oct; 99(1):165-7. PubMed ID: 9359518
[TBL] [Abstract][Full Text] [Related]
13. Hairy cell leukemia: early immunophenotypical detection and quantitative analysis by flow cytometry.
Babusíková O; Tomová A
Neoplasma; 2003; 50(5):350-6. PubMed ID: 14628088
[TBL] [Abstract][Full Text] [Related]
14. Selection of a panel of monoclonal antibodies for monitoring residual disease in peripheral blood and bone marrow of interferon-treated hairy cell leukaemia patients.
Falini B; Pileri SA; Flenghi L; Liberati M; Stein H; Gerli R; Minelli O; Martelli MF; Lauria F; Poggi S
Br J Haematol; 1990 Dec; 76(4):460-8. PubMed ID: 1702309
[TBL] [Abstract][Full Text] [Related]
15. Immunophenotype of hairy-cell leukaemia after cold polymerization of methyl-methacrylate embeddings from 50 diagnostic bone marrow biopsies.
Kreft A; Büsche G; Bernhards J; Georgii A
Histopathology; 1997 Feb; 30(2):145-51. PubMed ID: 9067739
[TBL] [Abstract][Full Text] [Related]
16. Bone marrow and splenic histology in hairy cell leukaemia.
Wotherspoon A; Attygalle A; Mendes LS
Best Pract Res Clin Haematol; 2015 Dec; 28(4):200-7. PubMed ID: 26614898
[TBL] [Abstract][Full Text] [Related]
17. Treatment of hairy cell leukemia with cladribine (2-chlorodeoxyadenosine) by subcutaneous bolus injection: a phase II study.
von Rohr A; Schmitz SF; Tichelli A; Hess U; Piguet D; Wernli M; Frickhofen N; Konwalinka G; Zulian G; Ghielmini M; Rufener B; Racine C; Fey MF; Cerny T; Betticher D; Tobler A;
Ann Oncol; 2002 Oct; 13(10):1641-9. PubMed ID: 12377655
[TBL] [Abstract][Full Text] [Related]
18. Recommendations of the SFH (French Society of Haematology) for the diagnosis, treatment and follow-up of hairy cell leukaemia.
Cornet E; Delmer A; Feugier P; Garnache-Ottou F; Ghez D; Leblond V; Levy V; Maloisel F; Re D; Zini JM; Troussard X;
Ann Hematol; 2014 Dec; 93(12):1977-83. PubMed ID: 24994538
[TBL] [Abstract][Full Text] [Related]
19. Long-lasting decrease of CD4+/CD45RA+ T cells in HCL patients after 2-chlorodeoxyadenosine (2-CdA) treatment.
Raspadori D; Rondelli D; Birtolo S; Lenoci M; Nardi G; Scalia G; Sestigiani C; Tozzi M; Marotta G; Lauria F
Leukemia; 1999 Aug; 13(8):1254-7. PubMed ID: 10450754
[TBL] [Abstract][Full Text] [Related]
20. Long-term outcome of hairy cell leukemia treated with 2-chlorodeoxyadenosine.
Jehn U; Bartl R; Dietzfelbinger H; Vehling-Kaiser U; Wolf-Hornung B; Hill W; Heinemann V
Ann Hematol; 1999 Mar; 78(3):139-44. PubMed ID: 10211756
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
